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ABSTRACT  
The functional properties of circulating CD8+ T cells have been associated with immune control 
of HIV. However, viral replication occurs predominantly in secondary lymphoid tissues, such as 
lymph nodes (LNs). We used an integrated single-cell approach to characterize effective 
HIVspecific CD8+ T cell responses in the LNs of elite controllers (ECs), defined as individuals 
who suppress viral replication to extremely low levels in the absence of antiretroviral therapy 
(ART). Higher frequencies of total memory and follicle-homing HIV-specific CD8+ T cells were 
detected in the LNs of ECs compared with the LNs of chronic progressors (CPs). Moreover, 
HIV-specific CD8+ T cells potently suppressed viral replication without demonstrable cytolytic 
activity in the LNs of ECs, which harbored substantially lower amounts of CD4+ T cell-
associated HIV DNA and RNA compared with the LNs of CPs. Single-cell RNA sequencing 
(scRNAseq) analyses further revealed a distinct transcriptional signature among HIV-specific 
CD8+ T cells from the LNs of ECs, typified by the downregulation of inhibitory receptors and 
cytolytic molecules and the upregulation of multiple cytokines, predicted secreted factors, and 
components of the protein translation machinery. Collectively, these results provide a 
mechanistic framework to expedite the identification of novel antiviral factors, highlighting a 
potential role for the localized deployment of non-cytolytic functions as a determinant of immune 
efficacy against HIV.  
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INTRODUCTION  
AIDS is a persistent global health issue with no existing vaccine or cure. Most individuals 
infected with HIV experience high levels of ongoing viral replication, leading to a progressive 
loss of CD4+ T cells and disease onset in the absence of antiretroviral therapy (ART). However, a 
small subset of HIV-infected individuals (< 1%), termed elite controllers (ECs), spontaneously 
control viral replication below the limit of detection and generally do not progress to AIDS. It is 
established that virus-specific CD8+ T cells are critical determinants of the EC phenotype in 
humans and rhesus macaques (1, 2). In addition, HIV-specific CD8+ T cells in ECs are 
qualitatively distinct from HIV-specific CD8+ T cells in chronic progressors (CPs), typically 
displaying enhanced polyfunctionality (3, 4), cytolytic activity (5-7), and proliferative capacity 
(5, 8), as well as a more differentiated memory phenotype and a characteristic specificity profile 
(4, 9-11). These attributes have been documented primarily among circulating lymphocytes, 
however, whereas HIV replication occurs predominantly in lymphoid tissues (LTs) (12-15).   
  
LTs are major reservoir sites for HIV. Recent studies have further demonstrated that almost 99% 
of viral RNA (vRNA)+ cells in SIV-infected rhesus macaques occur in LTs (16), reinforcing the 
need to understand anatomically colocalized mechanisms of immune control. It has long been 
known that circulating CD8+ T cells are more cytolytic than CD8+ T cells in the LTs of donors 
infected with HIV (17). Moreover, a state of immune privilege exists in LTs, which limits 
immunosurveillance by cytolytic HIV-specific CD4+ and CD8+ T cells (18, 19). In conjunction 
with the identification of distinct LT-resident memory CD8+ T cell subsets (20-22), these 
observations suggest that HIV-specific CD8+ T cells limit viral replication in LTs via effector 
mechanisms that differ from those employed by circulating HIV-specific CD8+ T cells (22). It 
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also seems reasonable to propose that non-cytolytic suppression rather than cytolytic eradication 
dictates effective immune control of HIV, given reports of ongoing viral evolution (23, 24) and 
the presence of replication-competent viral strains in ECs (25). However, this proposition 
remains unproven to date, because previous studies have not defined the antiviral efficacy and 
functional characteristics of HIV-specific CD8+ T cells in the LTs of ECs.  
  
In this study, we used a variety of methodological approaches, including polychromatic flow 
cytometry and single-cell RNA sequencing (scRNAseq) analyses, to compare the functional and 
transcriptional properties of HIV-specific CD8+ T cells in the peripheral blood and lymph nodes 
(LNs) of ECs and CPs. Our findings demonstrate that immune control of viral replication is 
associated with the occurrence of polyfunctional HIV-specific memory CD8+ T cells that exhibit 
a weak cytolytic signature and preferentially home to B cell follicles in the LNs of ECs.  
  
    
RESULTS  
CD8+ T cells actively suppress HIV replication in the LNs of ECs  
To define the nature of protective CD8+ T cell responses in LNs, where HIV replicates in vivo, 
we obtained tissue biopsies (cervical, iliac, inguinal, mesenteric, pelvic, or peribronchial LNs) 
and fine needle aspirates (inguinal LNs) from HIV+ individuals on antiretroviral therapy (ART) 
and untreated HIV+ individuals categorized as acute seroconverters, ECs, or CPs 
(Supplementary Table 1). Extremely low levels of vRNA+ cells were detected in the LNs of 
ECs compared with the LNs of CPs (p = 0.0174, Fig. 1a). In line with previous findings (26), 
vRNA+ cells were visualized in the B cell follicles and the paracortical region (T cell zone) 
(Supplementary Fig. 1). Total CD4+ T cell-associated HIV DNA and RNA measurements were 
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also lower in the LNs of ECs compared with the LNs of CPs (p = 0.0428 and p = 0.0016, 
respectively, Fig. 1b), and CD8+ T cells from the LNs of ECs displayed greater efficacy in a 
modified viral suppression assay (27) compared with CD8+ T cells from the LNs of CPs (p = 
0.0224) and CD8+ T cells from the LNs of HIV+ individuals on ART (p = 0.0323, Fig. 1c). These 
results suggest that CD8+ T cells maintain active control of HIV replication in the LNs of ECs.  
  
  
CD8+ T cells exhibit weak cytolytic activity in the LNs of ECs  
In peripheral blood, the frequency of cytolytic HIV-specific CD8+ T cells, defined by expression 
of perforin and granzyme B, correlates inversely with plasma viral load (pVL) (5-7). We 
therefore hypothesized that enhanced CD8+ T cell-mediated cytolytic activity may underlie viral 
control in the LNs of ECs. However, lower frequencies of perforin+, granzyme B+, and perforin+ 
granzyme B+ memory CD8+ T cells were detected in the LNs of ECs compared with the LNs of 
CPs (p = 0.0001, p = 0.0025, and p = 0.0003, respectively, Fig. 2a and Supplementary Fig. 
2a,b). The frequency of perforin+ granzyme B+ memory CD8+ T cells also correlated positively 
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with pVL (r = 0.8213, p < 0.0001, Fig. 2b). Importantly, perforin and granzyme B were highly 
expressed among circulating memory CD8+ T cells in donor-matched samples from ECs, 
indicating that the non-cytolytic phenotype was restricted to LNs (Supplementary Fig. 2c). 
Immunohistochemical analyses confirmed that fewer perforin+ CD8+ T cells, but not granzyme 
B+ CD8+ T cells, were present in the LNs of ECs compared with the LNs of CPs (Fig. 2c,d). 
  
We then used human leukocyte antigen (HLA) class I-matched tetramers to examine HIV-
specific CD8+ T cells. Higher frequencies of tetramer+ CD8+ T cells were present in the LNs of 
ECs compared with the LNs of CPs (p = 0.04) (Fig. 2e). However, these HIV-specific CD8+ T 
cells expressed very low levels of perforin and granzyme B, especially in the LNs of ECs (Fig. 
2f). In response to cognate peptide stimulation, HIV-specific CD8+ T cells from the LNs of ECs 
also failed to upregulate either perforin or granzyme B, unlike CD8+ T cells paired by donor and 
specificity from the peripheral blood of ECs (Supplementary Fig. 3a). Moreover, CD8+ T cells 
from the LNs of ECs did not exhibit discernable expression of perforin or granzyme B after 3 
days in culture with HIV-infected CD4+ T cells from the same LNs (Supplementary Fig. 3b).  
  
To quantify rather than infer cytolytic activity, we performed ex vivo redirected killing assays 
based on the detection of active caspase 3, which reliably identified non-viable target cells 
(Supplementary Fig. 4a,b). In contrast to circulating CD8+ T cells, donor-matched CD8+ T cells 
from the LNs of ECs largely failed to kill P815 mastocytoma target cells pre-coated with a CD3-
specific monoclonal antibody, which mimics signals delivered via the TCR (Fig. 2g). A similar 
anatomical discrepancy was observed using paired samples from CPs (Fig. 2g). Moreover, no 
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significant increases in target cell death were observed after extended incubation (24 hours), 
ruling out the involvement of temporally delayed killing mechanisms (Supplementary Fig. 4b).  
  
Collectively, these data suggest that cytolytic activity does not contribute mechanistically to the 
protective attributes of CD8+ T cells in the LNs of ECs.  
  
CD8+ T cells display increased follicle-homing potential in the LNs of ECs  
B cell follicles are thought to represent immunoprivileged sites that potentiate HIV persistence as 
a consequence of limited immunosurveillance by CD8+ T cells (2, 28-31). Previous studies have 
also demonstrated an inverse correlation between the frequency of follicle-homing (CXCR5+) 
CD8+ T cells and pVL (18, 32, 33). In line with these findings and the relative absence of vRNA+ 
cells in the B cell follicles of ECs (Fig. 1b), we detected higher frequencies of CXCR5+ memory 
CD8+ T cells in the LNs of ECs compared with the LNs of CPs (p = 0.0288, Fig. 2h). A similar 
trend was observed for HIV-specific CXCR5+ CD8+ T cells (p = 0.124, Fig. 2i). However, 
perforin and granzyme B were typically expressed at higher frequencies among CXCR5– CD8+ T 
cells compared with CXCR5+ CD8+ T cells, reaching significance in the ART cohort (p = 
0.0026, Fig. 2j). 
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HIV-specific CD8+ T cells have a distinct transcriptional profile in the LNs of ECs  
To identify potential correlates of viral control in LTs, we analyzed the transcriptomes of resting 
HIV-specific CD8+ T cells from the LNs of ECs and CPs (Fig. 3a). The scRNAseq data were 
initially processed using an unsupervised kernel-based algorithm to determine cellular similarity 
in a global and unbiased manner (see Materials and Methods). Clusters of transcriptionally 
distinct cells were present in each donor group (Fig. 3b). Importantly, normalized expression 
levels of PRF1 and GZMB were lower in HIV-specific CD8+ T cells from the LNs of ECs 
compared with HIV-specific CD8+ T cells from the LNs of CPs (Fig. 3c), and normalized 
expression levels of transcripts encoding other cytolytic molecules, including GZMA, GZMH, 
GZMK, GZMM, FASL, and TNFSF10 (34, 35), were either comparable between groups or 
enriched in HIV-specific CD8+ T cells from the LNs of CPs compared with HIV-specific CD8+ T 
cells from the LNs of ECs (Fig. 3c).   
  
We then applied a supervised machine-learning algorithm to determine which transcripts best 
characterized HIV-specific CD8+ T cells from the LNs of ECs and HIV-specific CD8+ T cells 
from the LNs of CPs (see Materials and Methods). A set of 200 genes reliably distinguished 
each donor group (average error < 0.5%) (Fig. 3d). Hierarchical clustering of these ‘feature’ 
genes clarified the key inter-group differences (Fig. 3e), most of which could be assigned to 
immune response pathways via gene ontology (GO) analysis (Fig. 3f), and t-Distributed 
Stochastic Neighbor Embedding (tSNE) visualization generated two distinct clusters of HIV-
specific CD8+ T cells that clearly differentiated ECs from CPs (Fig. 3g). Overlaying transcript 
levels of specific ‘feature’ genes onto the tSNE plot further revealed that HIV-specific CD8+ T 
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cells from the LNs of CPs preferentially expressed inhibitory receptors, such as TIGIT, LAG3, 
CD244, as well as the terminal differentiation marker KLRG1 and the transcription factor 
EOMES, collectively indicating an exhausted phenotype (36-38), whereas HIV-specific CD8+ T 
cells from the LNs of ECs preferentially expressed IL7R, which is crucial for homeostasis (39), 
and several chemokines/cytokines, such as CCL5 and IL32, collectively indicating a highly 
functional memory phenotype (Fig. 3g).  
  
To confirm and extend these findings, we reanalyzed our scRNAseq data using the 
reproducibilityoptimized test statistic (ROTS) (40), a Bayesian model of differential distribution 
(scDD) (41), and Seurat (42). A total of 2,264 differentially expressed genes achieved 
significance in at least two of these independent analytical frameworks (Supplementary Fig. 5a 
and Supplementary Table 2). These genes were enriched for immune-related terms, such as 
‘immune response’, ‘immune system process’, and ‘defense response’, in GO analyses 
(Supplementary Fig. 5b). Of particular note, ingenuity pathway analysis (IPA) further identified 
a core cassette of 11 transcripts encoding predicted secreted factors that were selectively 
upregulated in HIV-specific CD8+ T cells from the LNs of ECs, including TNF, CCL5, RNASE1, 
and IL32, which have been shown to suppress HIV replication (43-49) (Supplementary Fig. 5c).  
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HIV-specific CD8+ T cells are polyfunctional and translate proteins efficiently in the LNs of ECs   
In response to cognate peptide stimulation, higher frequencies of HIV-specific CD8+ T cells from 
the LNs of ECs produced TNF compared with HIV-specific CD8+ T cells from the LNs of CPs 
(p = 0.0003) and HIV-specific CD8+ T cells from the LNs of HIV+ individuals on ART (p = 
0.039) (Fig. 4a,b). A similar trend was observed for IFNγ, MIP-1β, and IL-2 (Fig 4b). Moreover, 
HIV-specific CD8+ T cells from the LNs of ECs were frequently polyfunctional, whereas HIV-
specific CD8+ T cells from the LNs of CPs were predominantly monofunctional (Fig. 4c,d).  
  
To seek an explanation for these findings, we returned to our GO analysis of the 200 ‘feature’ 
genes. In addition to immune-related terms, several protein translation-related terms were also 
highlighted, including ‘SRP-dependent cotranslational protein targeting to membrane’, ‘protein 
targeting to ER’, and ‘translation initiation’ (Fig. 3f). Most of these genes encoded ribosomal 
protein subunits that were preferentially expressed in HIV-specific CD8+ T cells from the LNs of 
ECs (Fig. 4e). Gene set enrichment analysis (GSEA) similarly identified ‘translation’, 
‘SRPdependent cotranslational protein targeting to membrane’, and ‘3’ UTR-mediated 
translation regulation’ as the most highly enriched gene sets in the EC group (Fig. 4f).   
  
We then performed in vitro translation experiments to measure the uptake of fluorescently 
labeled L-homopropargylglycine (HPG) in resting and activated CD8+ T cells from the LNs of 
ECs, CPs, and HIV+ individuals on ART. Higher frequencies of resting memory CD8+ T cells 
from the LNs of ECs incorporated HPG into newly synthesized proteins compared with resting 
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memory CD8+ T cells from the LNs of CPs (p = 0.003) (Fig. 4g). These differences emanated 
primarily from the central memory compartment (Fig. 4g). After stimulation with HIV-derived 
peptides or anti-CD3, functionally responsive CD8+ T cells from the LNs of ECs also 
incorporated more HPG than functionally responsive CD8+ T cells from the LNs of CPs (p = 
0.008 and p = 0.01, respectively) and functionally responsive CD8+ T cells from the LNs of HIV+ 
individuals on ART (p = 0.004 and p = 0.04, respectively) (Fig. 4g). These results suggest that 
efficient protein translation can explain, at least in part, the antiviral efficacy and polyfunctional 
nature of HIV-specific CD8+ T cells in ECs. 
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DISCUSSION  
In this study, we found that weakly cytolytic CD8+ T cells homed to B cell follicles, which 
constitute a major viral reservoir in vivo (2, 15), and potently suppressed HIV replication in the 
LTs of ECs. Moreover, these LN-derived CD8+ T cells downregulated inhibitory receptors, 
upregulated multiple soluble factors and cytokines, and displayed efficient protein translation. 
Although cause and effect arguments can always be made in the context of human studies, these 
features likely identify a protective immune signature, because CD8+ T cells from the LNs of 
HIV+ individuals on ART failed to acquire the characteristics of CD8+ T cells from the LNs of 
ECs.  
  
Ultrasensitive assays have revealed ongoing viral replication and evolution in the plasma of ECs 
(23-25). In line with the notion of anatomically localized immune control, we detected very few 
vRNA+ cells and very low amounts of HIV DNA and RNA in the LNs of ECs. We also found 
that CD8+ T cells from the LNs of ECs suppressed HIV replication in autologous CD4+ T cells 
far more efficiently than CD8+ T cells from the LNs of CPs and CD8+ T cells from the LNs of 
HIV+ individuals on ART. Depletion studies in non-human primates have shown that CD8+ cells 
are required to maintain effective control of SIV (2, 50). Moreover, we and others have 
demonstrated that circulating CD8+ T cells exhibit superior cytolytic activity in ECs (6, 7). It was 
therefore surprising to find that cytolytic molecules were expressed at lower levels in CD8+ T 
cells from the LNs of ECs compared with CD8+ T cells from the LNs of CPs, aligning with a 
general state of limited immunosurveillance in HIV-infected LTs (42). Although we cannot 
exclude a role for cytolytic mechanisms, especially during the early stages of infection, our data 
clearly show that a potent cytolytic response is not a prerequisite for durable immune-mediated 
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suppression of HIV. These data are consistent with the observation that terminally differentiated 
effector memory T cells, which are highly cytolytic, primarily circulate in the blood and patrol 
highly vascularized organs rather than other tissue sites (51). The general exclusion of cytolytic 
CD4+ and CD8+ T cells from LTs is likely a conserved feature of the immune system that has 
evolved to limit the destruction of antigen-presenting cells and stromal tissues under conditions 
of persistent stimulation. Non-cytolytic effector functions may therefore be necessary for 
effective immune control of viruses and other pathogens that specifically target these sites. 
Indeed, an equivalent scenario has been described in the liver, where hepatitis B virus-specific 
CD8+ T cells eliminate the infection without killing hepatocytes via the secretion of IFNγ and 
TNF (52). Similarly, non-cytolytic mechanisms of immune control have been described in the 
context of infection with herpes simplex virus, measles virus, and vaccinia virus (53, 54), as well 
as HIV and SIV infection (55-57). Our results adds to this body of literature and further suggest 
that spatial distribution and the efficient translation of antiviral proteins are key features of a 
protective HIV-specific CD8+ T cell response in LTs.   
  
In summary, we have shown that non-cytolytic CD8+ T cells with distinct functional, phenotypic, 
and transcriptional signatures, including the upregulation of known or predicted soluble factors, 
efficient protein translation, and a high level of ribosome biogenesis, suppress viral replication in 
the LNs of ECs. These observations are highly pertinent in light of current “kill” strategies 
designed to achieve a functional cure for HIV (58). Collectively, our data support a model in 
which viral suppression rather than viral eradication dictates immune efficacy, without excluding 
a role for cytolytic mechanisms, and provide fresh impetus in the search for novel antiviral 
factors that may complement existing therapies for HIV (59).    
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MATERIALS AND METHODS  
Samples  
Peripheral blood samples, tissue biopsies (cervical, iliac, or inguinal LNs), and fine needle 
aspirates (inguinal LNs) were obtained from HIV+ individuals on ART (n = 10) and untreated 
HIV+ individuals categorized as acute seroconverters (Fiebig stage IV–VI, n = 7), ECs (n = 12), 
or CPs (n = 13). Donors were recruited at three different sites: INER-CIENI, Mexico City, 
Mexico; the University of California, San Francisco, USA; and the University of Pennsylvania, 
Philadelphia, USA. Clinical characteristics are summarized in Supplementary Table 1. 
Paraffin-embedded LN slides from CPs (n = 7) for microscopy experiments were obtained via 
the Pathology Core at the Hospital of the University of Pennsylvania (Philadelphia). All donors 
provided informed consent in line with protocols approved by the INER-CIENI Ethics 
Committee, the Federal Commission for the Protection against Sanitary Risk (COFEPRIS), and 
the Institutional Review Boards of the University of California (San Francisco) and the 
University of Pennsylvania (Philadelphia). Sample sizes were not predetermined by power 
calculations, and investigators were not blinded to group identity during the course of the study.  
  
Peripheral blood mononuclear cells (PBMCs) were isolated using standard density gradient 
centrifugation, and LN mononuclear cells (LNMCs) were collected from whole biopsies via 
mechanical homogenization. Fine needle aspirates were processed for immediate 
experimentation. PBMCs and LNMCs were cryopreserved at –140 °C.  
  
RNAscope  
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Next-generation in situ hybridization was performed on LN biopsies as described previously 
(60).  
  
qPCR quantification of cellular HIV-1 DNA and RNA  
Cell-associated DNA and RNA were purified using an AllPrep DNA/RNA Mini Kit (Qiagen), 
concentrated in a SpeedVac System (Thermo Fisher Scientific), and normalized to cell 
equivalents via quantitative PCR (qPCR) with reference to genomic telomerase reverse 
transcriptase for DNA and expressed ribosomal protein lateral stalk subunit P0 for RNA (Thermo 
Fisher Scientific). Total cell-associated HIV DNA and RNA were quantified via qPCR using a 
QuantStudio 6 Flex RealTime PCR System (Applied Biosystems) with the LTR-specific primers 
F522-43 (5’-GCCTCAATAAAGCTTGCCTTGA-3’; HXB2  522–543)  and  R626-
43 (5’-GGGCGCCACTGCTAGAGA-3’; HXB2 626–643) and a FAM-BQ probe 
(5’CCAGAGTCACACAACAGACGGGCACA-3’). Cell-associated HIV DNA copy number 
was determined in a final reaction volume of 20 µL incorporating 4 pmol of each primer, 4 pmol 
of probe, 5 µL of DNA, and 10 µL of 2x TaqMan Universal Master Mix II, with UNG (Thermo 
Fisher Scientific). Thermal parameters were as follows: 50 °C for 2 minutes (1 cycle), 95 °C for 
10 minutes (1 cycle), and 95 °C for 15 seconds followed by 59 °C for 1 minute (60 cycles). Cell-
associated HIV RNA copy number was determined in a final reaction volume of 20 µL 
incorporating 4 pmol of each primer, 4 pmol of probe, 5 µL of RNA, 0.5 µL of reverse 
transcriptase, and 10 µL of 2x TaqMan RNA-to-CT 1-Step (Thermo Fisher Scientific). Thermal 
parameters were as follows: 48 °C for 20 minutes (1 cycle), 95 °C for 10 minutes (1 cycle), and 
95 °C for 15 seconds followed by 59 °C for 1 minute (60 cycles). For HIV DNA measurements, 
external quantification standards were prepared from the ACH-2 cell line in a background of 
HIV– human cellular DNA, calibrated against the Division of AIDS Virology Quality Assurance 
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Program HIV-1 DNA Quantification Standard (National Institutes of Health AIDS Reagent 
Program). For HIV RNA measurements, external quantification standards were prepared from 
full-length NL4-3 virion RNA, and copy number was determined using a Real-Time HIV-1 Viral 
Load Assay (Abbott Molecular), calibrated against the Division of AIDS Virology Quality 
Assurance Program HIV-1 RNA Quantification Standard (National Institutes of Health AIDS 
Reagent Program). Copy number for all samples was determined in triplicate by extrapolation 
against a seven-point standard curve (1–10,000 cps).  
  
Peptide stimulation assay  
Cryopreserved LNMCs and PBMCs were thawed and rested overnight at 37 °C in RPMI medium 
supplemented with 10% fetal bovine serum, 1% L-glutamine, and 1% penicillin/streptomycin 
(R10). Cells were then washed in R10 and resuspended at 2 x 106 cells/mL. Approximately 0.5 x 
106 to 1 x 106 cells were used per condition, with lower bounds defined by cell availability in 
each sample. All stimulation conditions included anti-CD28 and anti-CD49d (each at 1 µg/mL, 
BD Biosciences), GolgiStop (0.7 µL/mL, BD Biosciences), and brefeldin A (1 µg/mL, Sigma-
Aldrich). Cells were stimulated for 6 hours at 37 °C with peptides matching optimal epitopes 
derived from HIV (each at a final concentration of 1 µg/mL, New England Biolabs). Positive 
controls incorporated staphylococcal enterotoxin B (1 µg/mL, Sigma-Aldrich). Degranulation 
was detected via the addition of anti-CD107a–PE-Cy5 (eBioH4A3, eBioscience) at the start of 
the assay to capture surface-mobilized events in real time (61).  
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Flow cytometry  
LNMCs and PBMCs were stained with anti-CCR7–APC-Cy7 (G043H7, BioLegend) for 10 
minutes at 37 °C. Cells were then labeled with LIVE/DEAD Fixable Aqua (Thermo Fisher 
Scientific) for 10 minutes at room temperature to identify non-viable events, stained with a 
cocktail of directly-conjugated monoclonal antibodies for 20 minutes at room temperature to 
detect surface markers, fixed/permeabilized using a Cytofix/Cytoperm Kit (BD Biosciences), 
stained with another cocktail of directly-conjugated monoclonal antibodies for 1 hour at room 
temperature to detect intracellular markers, and fixed in 1% paraformaldehyde (Sigma-Aldrich). 
Data were acquired using an LSRII flow cytometer (BD Biosciences) and analyzed with FlowJo 
software v9.9.4 (Tree Star Inc.).  
  
Antibodies   
The following directly-conjugated reagents were used in flow cytometry experiments. Tetramer 
panel: anti-CCR7–APC-Cy7 (G043H7, BioLegend), anti-CD14–BV510 (M5E2, BioLegend), 
anti-CD19–BV510 (HIB19, BioLegend), anti-CD3–BV711 (UCHT1, BioLegend), anti-CD4–PE-
Cy5.5 (S3.5, Thermo Fisher Scientific), anti-CD8–BV570 (RPA-T8, BioLegend), anti-CD27– 
BV785 (O323, BioLegend), anti-CD45RO–BV650 (UCHL1, BioLegend), anti-CD69–PE-Cy5 
(TP1.55.3, Beckman Coulter), anti-CD103–BV605 (2E7, BioLegend), anti-CXCR5–AF488 
(RF8B2, BD Biosciences), anti-perforin–PE-Cy7 (dG9, eBioscience), anti-granzyme B–AF700 
(GB11, BD Biosciences), anti-Tbet–PE-Dazzle (4B10, BioLegend), and anti-Eomes–AF647 
(WD1928, eBioscience). Peptide stimulation panel: anti-CD107a–PE-Cy5 (eBioH4A3, 
eBioscience), anti-CCR7–APC-Cy7 (G043H7, BioLegend), anti-CD14–BV510 (M5E2, 
BioLegend), anti-CD19–BV510 (HIB19, BioLegend), anti-CD3–BV711 (UCHT1, BioLegend), 
anti-CD4–PE-Cy5.5 (S3.5, Thermo Fisher Scientific), anti-CD8–BV570 (RPA-T8, BioLegend), 
		 22	 
anti-CD27–BV785 (O323, BioLegend), anti-CD45RO–BV650 (UCHL1, BioLegend), anti-
CXCR5–AF647 (RF8B2, BD Biosciences), anti-IFNγ–FITC (B27, BD Biosciences), anti-TNF–
BV605 (MAb11, BioLegend), anti-IL-2–APC-R700 (MQ1-17H12, BD Biosciences), anti-MIP-
1β–PE-Cy7 (D21-1351, BD Biosciences), anti-perforin–BV421 (B-D48, BioLegend), anti-
granzyme B–PE-TxRed (GB11, Thermo Fisher Scientific), and anti-Tbet–PE (4B10, 
eBioscience). Redirected killing assay panel: anti-active caspase 3–FITC (C92-605, BD 
Biosciences), anti-CD3–PE (SK7, BD Biosciences), and anti-perforin–PE-Cy7 (dG9, 
eBioscience). Suppression assay panel: anti-p24–FITC (KC57, Beckman Coulter), anti-CD14– 
BV510 (M5E2, BioLegend), anti-CD19–BV510 (HIB19, BioLegend), anti-CD3–BV711 
(UCHT1, BioLegend), anti-CD4–PE-Cy7 (RPA-T4, BioLegend), anti-CD8–BV570 (RPA-T8, 
BioLegend), anti-CD25–Tricolor (CD25-3G10, Thermo Fisher Scientific), anti-perforin–BV421 
(B-D48, BioLegend), and anti-granzyme B–PE-TxRed (GB11, Thermo Fisher Scientific). 
Translation assay panel: anti-CCR7–APC-Cy7 (G043H7, BioLegend), anti-CD14–BV510 
(M5E2, BioLegend), anti-CD19–BV510 (HIB19, BioLegend), anti-CD3–BV711 (UCHT1, 
BioLegend), anti-CD4–APC (S3.5, Thermo Fisher Scientific), anti-CD8–BV570 (RPA-T8, 
BioLegend), anti-CD45RO–BV650 (UCHL1, BioLegend), azide–AF488 (A10266, Thermo 
Fisher Scientific), anti-TNF–PE-Cy7 (MAb11, Thermo Fisher Scientific), and anti-IFNγ–AF700 
(B27, BD Biosciences). Viral quantification panel: anti-CCR7–APC-Cy7 (G043H7, BioLegend), 
anti-CD3–APC-R700 (UCHT1, BD Biosciences), anti-CD4–PE-Cy7 (RPA-T4, BioLegend), 
anti-CD8–PE-Cy5.5 (RPA-T8, eBiosciences), anti-CD14–BV510 (M5E2, BioLegend), anti-
CD19–BV510 (HIB19, BioLegend), anti-CD45RA–PE-CF594 (HI100, BD Biosciences), anti-
CXCR5–AF647 (RF8B2, BD Biosciences), and anti-PD-1–BV421 (EH12.2H7, BioLegend).  
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Tetramers  
HLA class I tetramers conjugated to BV421 or PE were produced as described previously (62).  
The following specificities were used to detect HIV-specific CD8+ T cells: A*0201-IV9  
(ILKEPVHGV), A*0201-SL9 (SLYNTVATL), A*0201-FK10 (FLGKIWPSHK), A*0201-TV9  
(TLNAWVKVV), A*2402-RW8 (RYPLTFGW), A*2402-KW9 (KYKLKHIVW), A*2402-RL9  
(RPMTYKGAL), B*0702-GL9 (GPGHKARVL), B*0702-HI10 (HPRVSSEVHI), B*0702-SM9  
(SPAIFQSSF), B*2705-KK10 (KRWIILGLNK), B*3501-VY10 (VPLDEDFRKY), B*3501NY9 
(NSSKVSQNY), B*5701-KF11 (KAFSPEVIPMF), B*5701-TW10 (TSTLQEQIGW),  
B*5701-ISW9 (ISPRTLNAW), and B*5701-QW9 (QASQEVKNW).  
  
Immunohistochemistry   
LN biopsy material was cut at a thickness of 5 µm and processed as described previously (63). 
Briefly, tissue sections were heated in 0.01% citraconic anhydride containing 0.05% Tween-20 
and incubated overnight at 4 oC with monoclonal or polyclonal antibodies specific for perforin 
(1:100, 5B10/VP-P967, Vector Laboratories Inc.) or granzyme B (1:200, HPA003418, Sigma-
Aldrich). Slides were then washed in TBS containing 0.05% Tween-20, and endogenous 
peroxidases were blocked using 1.5% (v/v) H2O2 in TBS, pH 7.4. Antigens were revealed using 
mouse Polink-1 or rabbit Polink-2 HRP in conjunction with ImmPACT DAB (Vector 
Laboratories Inc.) and Warp Red (Biocare Medical Inc.). Slides were then washed in H2O, 
counterstained with haematoxylin, mounted in Permount (Thermo Fisher Scientific), and scanned 
at 200x magnification using a ScanScope CS System (Aperio Technologies). Representative 
regions of interest (0.4 mm2) were identified visually, and high-resolution images were extracted 
		 24	 
from the whole-tissue scans. The percent area positive for CD4+ T cells was quantified using 
CellProfiler v3.1.5 (64).  
  
Single-cell RNAseq  
The experimental setup was described previously in Buggert et al. (22). Briefly, single HIV 
tetramer+ cells were index sorted directly into 96-well microtiter plates containing lysis buffer 
using a FACSAria II flow cytometer (BD Biosciences). Cellular nucleic acids were recovered 
using an RNEasy Plus Micro Kit (Qiagen) and RNAClean (SPRI) beads (Beckman Coulter). 
Performance was assessed using External RNA Controls Consortium (ERCC) RNA Spike-In 
Mix (Ambion). Reverse transcription was performed using oligo-dT primers, and cDNA was 
amplified over 22–24 PCR cycles using universal primers and Kapa HiFi HotStart ReadyMix 
(Kapa Biosystems). After clean-up, amplified cDNA was barcoded using Illumina Nextera 
libraries and sequenced to a depth of approximately 2 million 150 bp paired-end reads/cell on a 
HiSeq 4000 (Illumina). Whole transcriptome data were obtained from 221 cells (n = 552 sorted 
cells). 
  
Single-cell RNAseq analyses  
A kernel-method learning framework was used to assess the pairwise similarity between cells and 
compute the distance metric that best fitted the structure of the data 
(https://arxiv.org/pdf/1808.02061.pdf). Cell-to-cell similarity was learned using a rank-based, 
nonparametric function, and tSNE kernelization allowed the use of data from all available 
features. Dimensionality reduction was performed using kernel tSNE, wherein the pairwise 
similarity between cells was computed using the Semblance kernel as a distance measure. In 
determination of the cell-to-cell similarity matrix, the Gini index was used to account for the 
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distribution of each gene and weigh it appropriately in the kernel calculation. The Gini index 
enabled the prioritization of genes with high variance as the genes that were more likely to 
provide useful features for niche group detection. Single cells were then projected onto a two-
dimensional space using kernel tSNE, enabling intuitive visualization of hidden structures within 
the data. The supporting code is freely available online and can be implemented via the R 
Package Semblance (https://cran.rproject.org/web/packages/Semblance/index.html).  
  
For support vector machine (SVM) analyses, genes were selected using a t-score cut-off of p < 
0.01. Selected genes were then ranked using L0-norm regularization. The L0-norm-ranked gene 
lists were fed into the SVM algorithm for cross-validation (k-fold = 10) in subsets (increment = 
100 genes). The average prediction error for each cross-validation was used to determine how 
well each subset of genes classified the desired labels. All steps were performed in MATLAB 
(MathWorks). L0-norm regularization was implemented using the MATLAB Feature Selection 
Library (MathWorks).  
  
Differentially expressed genes were identified using three approaches: ROTS (40), which 
optimizes the t-statistics based on the inherent characteristics of the data; scDD (41) which is a 
differential expression analysis method that accounts for the possibility of multimodally 
distributed gene expression; and Seurat (42), which uses the non-parametric Mann-Whitney U-
test to assess the null hypothesis that a randomly selected mean expression value for a given gene 
in one group will have an equal chance of being less than or greater than a randomly selected 
mean expression value for the same gene in a second group. As different genes in the dataset 
exhibited different distribution properties, these approaches in combination allowed us to 
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winnow the list of differentially expressed genes, specifying a cut-off of p < 0.05 in at least two 
of the three outputs. The scDD p-values are reported for simplicity.  
  
The  topGO  package  Bioconductor  v3.8  was  used  for  GO  analyses  
(https://bioconductor.org/packages/release/bioc/html/topGO.html). GO terms associated with 
each gene were obtained using the August 2017 ENSEMBL Database. Significance was 
determined using the classic Fisher method. GSEA analyses were performed using software 
developed by the Broad Institute (65, 66).  
  
Redirected killing assay  
P815 mastocytoma target cells were labeled with LIVE/DEAD Violet (Thermo Fisher Scientific) 
and TFL4 (OncoImmun), washed twice in PBS, and incubated for 30 minutes at room 
temperature with anti-CD3 (5µg/mL, UCHT1, BioRad). CD8+ T cells were negatively selected 
from LNMCs or PBMCs using a CD8+ T Cell Enrichment Kit (StemCell Technologies). Isolated 
CD8+ T cells were rested in R10 for at least 45 minutes at 37 °C and then incubated with anti-
CD3-coated P815 cells at different effector-to-target ratios in a 96-well V-bottom plate for 4 
hours at 37 °C. Cells were then stained as described above (see Antibodies section) and acquired 
using an LSRII flow cytometer (BD Biosciences).  
 
Killing capacity was calculated by subtracting the frequency of active caspase3+ TFL4+ 
LIVE/DEAD– P815 cells in target-only wells from the frequency of active caspase3+ TFL4+ 
LIVE/DEAD– P815 cells in wells containing effector cells.  
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Viral suppression assay  
The viral suppression assay was modified from Sáez-Cirion et al. (27). Briefly, CD4+ T cells 
were positively selected from LNMCs or PBMCs using a CD4+ T Cell Enrichment Kit (StemCell  
Technologies) and activated using a cocktail of IL-2 (100 U/mL, Chiron), anti-CD3 (1 µg/mL, 
UCHT1, Bio-Rad), anti-CD28 (1 µg/mL, L293, BD Biosciences), and anti-CD49d (1 µg/mL, 
L25, BD Biosciences). Concurrently, autologous CD8+ T cells were negatively selected from 
LNMCs or PBMCs using a CD8+ T Cell Enrichment Kit (StemCell Technologies) and rested in 
R10. After 2 days, CD4+ T cells were infected with HIV-1 BAL by spinoculation and incubated 
with or without autologous CD8+ T cells in the absence of exogenous IL-2. Cells were harvested 
after a further 3 days, stained as described above (see Antibodies section), and acquired using an 
LSRII flow cytometer (BD Biosciences).  
  
Suppression capacity was calculated by dividing the frequency of p24+ CD4+ T cells in wells 
containing autologous CD8+ T cells by the frequency of p24+ CD4+ T cells in wells lacking 
autologous CD8+ T cells.  
  
HPG translation assay  
The protein translation assay was adapted from Araki et al. (67). Briefly, LNMCs were rested 
overnight and incubated for 30 minutes in methionine-free R10. The cultures were then 
supplemented with Click-iT HPG (100 µM, Thermo Fisher Scientific). Cells were stimulated 
with PepMix HIV (GAG) Ultra (2µg/mL/peptide, JPT Peptide Technologies), PepMix HIV 
(NEF) Ultra (2µg/mL/peptide, JPT Peptide Technologies), or anti-CD3 (5µg/mL, UCHT1, 
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BioRad) in the presence of GolgiStop (0.7 µL/mL, BD Biosciences) and brefeldin A (1 µg/mL, 
Sigma-Aldrich). After 6 hours, cells were stained as described above (see Antibodies section) 
and acquired using an LSRII flow cytometer (BD Biosciences), following the instructions in the 
Click-iT Plus Alexa Fluor Picolyl Azide Toolkit (Thermo Fisher Scientific).  
  
Statistics for non-sequencing data  
Data were checked for normality using the Shapiro-Wilk normality test. Parametric tests were 
used if the data passed the normality test, and non-parametric tests were used if the data failed 
the normality test. Multiple corrections for two-way ANOVA were performed using the two-
stage linear step-up procedure of Benjamini, Krieger, and Yekutieli. Specific tests are indicated 
in the relevant figure legends. Analyses were performed using R Studio or Prism v7.0 
(GraphPad). 
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FIGURE LEGENDS  
Figure 1. CD8+ T cells from the LNs of ECs display superior antiviral efficacy. a, Representative 
RNAscope images of paraffin-embedded LN biopsies from one EC and one CP (left) and data 
quantification across donor groups (right). TCZ, T cell zone; BCF, B cell follicle. b, 
Quantification of cell-associated HIV DNA and RNA from negatively-selected CD4+ T cells by 
qPCR. One data point on the DNA plot was adjusted from 0 to 1 for graphical purposes. Error 
bars represent mean and SEM. c, Representative flow plots from a viral suppression assay using 
LN-derived CD8+ T cells (left) and data quantification across donor groups (right). Dotted lines 
represent median and interquartile range. Significance was determined using the Kruskal-Wallis 
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test with Dunn’s correction (a), an unpaired t-test (b), or Welch’s ANOVA with Benjamini-
Hochberg correction (c). * p < 0.05, ** p < 0.01.  
  
Figure 2. Cytolytic CD8+ T cells are rare in the LNs of ECs. a, Representative flow plots 
showing perforin and granzyme B expression in LN-derived memory CD8+ T cells (left) and data 
quantification across donor groups (right). b, Correlation between the frequency of perforin+ 
granzyme B+ LN memory CD8+ T cells and pVL. Values for pVL below the limit of detection 
were plotted as 40 copies/mL. Significance was determined using Spearman’s rank correlation. c, 
d, Representative immunohistochemistry images of LN biopsies (left) stained for perforin (c) or 
granzyme B (d) and data quantification across donor groups (right). e, Representative flow plots 
showing HIV-specific tetramer staining of LN-derived memory CD8+ T cells (left) and data 
quantification across donor groups (right). Each dot represents a distinct tetramer+ population in 
the quantification plot. f, Representative flow plots showing HIV-specific tetramer+ cells 
(colored contours) overlaid on total LN-derived memory CD8+ T cells (grey background) gated 
to display perforin and granzyme B expression (left) and data quantification across donor groups 
(right). Each dot represents a distinct tetramer+ population in the quantification plot. g, 
Representative flow plots of redirected killing assays (left) and data quantification across donor 
groups (right). h, Representative flow plots showing CXCR5 expression on LN-derived memory 
CD8+ T cells (left) and data quantification across donor groups (right). i, Quantification of 
CXCR5 expression on LN-derived tetramer+ memory CD8+ T cells. Each dot represents a 
distinct tetramer+ population. j, Representative flow plots showing perforin and granzyme B 
expression in LN-derived CXCR5+ and CXCR5– memory CD8+ T cells (left) and data 
quantification across donor groups (right). Error bars represent median and interquartile range. 
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Significance was determined using the Kruskal-Wallis test with Dunn’s correction (a, c, d, e, f, 
h, i, k) or a two-way ANOVA (g). * p < 0.05, ** p < 0.01, *** p < 0.001.  
  
Figure 3. Distinct transcriptomic signatures characterize HIV-specific CD8+ T cells from the 
LNs of ECs and CPs. a, Set-up of the scRNAseq experiment, including data exclusion criteria. b, 
tSNE visualization of the unsupervised kernel-based algorithm. c, Violin plots of cytolysis-
related genes showing z-normalized expression levels. d, Average percent error of k-fold cross-
validation of support vector machine (SVM) models using subsets of the L0-norm-ranked gene 
list. Each crossvalidation was reiterated 100 times. e, Heatmap showing z-normalized expression 
of the 200 feature genes. f, Gene ontology (GO) analysis of the feature gene list using topGO. 
The top 25 enriched terms were reported, and p-values were calculated using the classic Fisher 
method. g, tSNE feature plots showing the distribution of gene expression. tSNE coordinates 
were calculated using the first 50 principal components and iterated 1,000 times. The color 
gradient displays relative log-normalized gene expression levels. Significance was determined 
using scDD calculations (c, g). * p < 0.05, ** p < 0.01, *** p < 0.001.   
Figure 4. Polyfunctionality is associated with protein translation efficiency in HIV-specific 
CD8+ T cells from the LNs of ECs. a, Representative flow plots showing the production of TNF 
and IL-2 by HIV-specific CD8+ T cells from the LNs of one EC and one CP in response to 
cognate peptide stimulation. Plots were pre-gated on total memory CD8+ T cells. b, 
Quantification of cytokine production by HIV-specific CD8+ T cells from LNs. The total 
response for each readout was determined by summing the corresponding frequencies after 
background subtraction of all Boolean gates using permutations of CD107a, IFNγ, TNF, MIP-1β, 
and IL-2. Error bars represent median and interquartile range. c, Polyfunctionality plot of HIV-
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specific CD8+ T cells from LNs. Only combinations of 4 and 5 functions are shown. Error bars 
represent mean and SEM. d, Pie charts summarizing all combinations of functions. e, Heatmap 
showing z-normalized expression levels of genes from the feature list identified by GO protein 
translation terms. f, Gene set enrichment analysis (GSEA) of the scRNAseq data with reference 
to the Reactome Pathway Database, reporting the top 10 enriched pathways in ECs and CPs. g, 
Quantification of protein translation efficiency in LN-derived CD8+ T cells. LNMCs were 
incubated with HPG in methionine-free medium for 6 hours in the presence or absence of HIV-
derived peptides or anti-CD3. Responding cells were defined using Boolean gating for IFNγ+ 
and/or TNF+ events. CM, central memory; EM, effector memory. Error bars represent mean and 
SEM. Significance was determined using a one-way ANOVA (d) or a two-way ANOVA (b, g). 
* p < 0.05, ** p < 0.01, *** p < 0.001.  
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Supplementary Figure 1. HIV RNA is present in B cell follicles and the T cell zone in LNs. a, 
Gating scheme used to sort LN-derived CD4+ T cell subsets for viral quantification. 
Representative flow plots were generated from the LNs of one EC. b, Quantification of HIV 
RNA in LN-derived CD4+ T cell subsets by qPCR. The limit of detection value was used in the 
absence of detectable HIV RNA (open circles). c, Percent frequency of vRNA+ cells in B cell 
follicles, as determined by RNAscope. Error bars represent mean and SEM (b) or median and 
interquartile range (c). Significance was determined using a two-way ANOVA (b) or the 
Kruskal-Wallis test with Dunn’s correction (c). ** p < 0.01, *** p < 0.001.  
  
  
Supplementary Figure 2. CD8+ T cells from the LNs of ECs express low levels of perforin and 
granzyme B. a, Gating scheme used in flow cytometry experiments. Representative plots were 
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generated from the LNs of one EC. All flow cytometry data shown in this report were pre-gated 
on memory CD8+ T cells unless specified otherwise. b, Quantification of perforin and granzyme 
B expression in LN-derived CD8+ T cells across donor groups. c, Representative flow plots 
showing perforin and granzyme B expression in matched peripheral blood and LN-derived CD8+ 
T cells from one EC (left) and data quantification across donor groups (right). Significance was 
determined using the Kruskal-Wallis test with Dunn’s correction (b) or the Wilcoxon matched 
pairs signed rank test (c). * p < 0.05, ** p < 0.01, *** p < 0.001.  
  
 
Supplementary Figure 3. CD8+ T cells from the LNs of ECs do not upregulate cytolytic 
molecules in response to cognate antigen exposure. a, LNMCs were stimulated for 6 hours with 
peptides representing optimal epitopes derived from HIV. Perforin and granzyme B were 
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quantified in HIV-specific CD8+ T cells. Colored dots in the representative flow plots (left) 
depict HIV-specific CD8+ T cells defined by the expression of at least one of the following 
markers: CD107a, IFNγ, TNF, MIP-1β, or IL-2. Black and red numbers indicate the frequency of 
HIV-specific CD8+ T cells before and after background subtraction, respectively. b, Frequency 
of LN-derived perforin+ granzyme B+ CD8+ T cells after 3 days in culture with HIV-infected 
autologous LN-derived CD4+ T cells, as shown in Fig. 1c. Significance was determined using the 
Kruskal-Wallis test with Dunn’s correction (a) or an unpaired t-test (b). * p < 0.05.  
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Supplementary Figure 4. Active caspase 3 detection captures the majority of killed target cells. 
CD8+ T cells isolated from the LNs, tonsils, and peripheral blood of HIV– individuals were 
incubated with anti-CD3-coated P815 cells at an effector:target ratio of 6:1 for 4 or 24 hours. a, 
Representative flow plots showing the detection of killed target cells via active caspase 3 versus 
LIVE/DEAD Aqua (L/D Aqua). Numbers represent frequencies of cells in each gate before 
(blue) or after background subtraction (red). b, Breakdown of the total killing after 4 hours. 
Casp, active caspase 3. Each pie chart represents total killing after background subtraction. c, 
Summary plot of redirected killing assays at 4 hours and 24 hours. % target killed represents the 
sum of Casp–Aqua+, Casp+Aqua+, and Casp+Aqua– after background subtraction. Error bars 
represent mean and SEM. Significance was determined using a two-way ANOVA (c). n.s., not 
significant.  
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Supplementary Figure 5. Differential expression analysis of the scRNAseq data. a, Venn 
diagram showing the overlap of differentially expressed genes detected by each of the three 
algorithms. A total of 2,264 genes achieved significance (p < 0.05) in at least two of the three 
algorithms. These genes are listed in Supplementary Table 2. b, The top 25 GO terms enriched 
among the 2,264 differentially expressed genes. c, List of secreted molecules that were 
upregulated in ECs, as determined by IPA. Expression p-values were derived from the scDD 
algorithm. Expr Log Ratio represents log fold-change values obtained from the ROTS algorithm; 
positive values indicate higher expression levels in ECs relative to CPs.  
  
Supplementary Table 1. Clinical characteristics of donors included in this study. Values 
represent median and interquartile range.  
 EC ART CP Acute 
Number 12 14 18 7 
Site San	Francisco	(USA) San	Francisco	(USA),	Philadelphia	(USA),	Mexico	City	
(Mexico) 
Mexico	City	(Mexico) Mexico	City	(Mexico) 
Age 52	(47-59) 40	(32-58) 31	(24-37) 23	(20-27) 
Gender 10	 Males	 /	 1	 Female	 /	 1	 Male	 to	
Female 
8	Males	/	1	Female	/	5	No	Info 10	 Males	 /	 1	 Female	 /	 7	 No	
Info 
7	Males	/	0	Female 
Viral	 Load	
(copies/mL) 
<40 <40 51,396	(12,845-213,173) 1,996,027	 (1,297,461-
4,421,034) 
CD4	Count 881	(660-1172) 544	(359-601) 348	(175-521) 306	(238-370) 
  
  
Supplementary Table 2. Complete list of 2,264 genes that were differentially expressed 
between HIV-specific CD8+ T cells from the LNs of ECs and HIV-specific CD8+ T cells from 
the LNs of CPs. Expression p-values were derived from all three algorithms. Log fold-change 
values were obtained from the ROTS algorithm; positive values indicate higher expression levels 
in ECs relative to CPs.  
  
	 
